[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542407":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":63,"collaborators":28,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":28,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":28,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":28,"overallStatus":45,"whyStopped":28,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BPd","EXPERIMENTAL","BPd regimen (Bortezomib, pomalidomide, and dexamethasone) will be applied every 28 days until progression of disease, unacceptable toxicity or subsequent therapy, for a maximum of six cycles.",[13,14,15],"Drug: Bortezomib","Drug: Pomalidomide","Drug: Dexamethasone",[17,24,29],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Bortezomib","Bortezomib 1.3mg\u002Fm2 sc weekly",[9],[23],"Velcade",{"type":18,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"Pomalidomide","4mg per day taken orally on 1-21 of repeated 28-day cycles",[9],null,{"type":18,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Dexamethasone","Dexamethasone 20mg-40mg weekly",[9],[34],{"name":35,"affiliation":5,"role":36},"Jin Lu","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":28,"email":42},"Yang Liu, Dr","CONTACT","86-13716926210","pkuphliuyang@vip.sina.com",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Beijing","Beijing Municipality","100044","China","CN",{"type":52,"coordinates":53},"Point",[54,55],116.39723,39.9075,{"lat":55,"lon":54},[58,62],{"name":59,"role":40,"phone":60,"phoneExt":28,"email":61},"Yang Liu","+8613716926210","pkuphliuyang@bjmu.edu.cn",{"name":35,"role":40,"phone":28,"phoneExt":28,"email":28},{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"SPONSOR_INVESTIGATOR","Jin Lu, MD","Principle Investigator","100542407","phase-2-bortezomib-pomalidomide-dexamethasone-for-systemic-al-amyloidosis-100542407",false,"NCT06342466","Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis","A Study of Bortezomib, Pomalidomide, Dexamethasone in Patients with Systemic AL Amyloidosis","Inclusion Criteria:\n\n1. Diagnosis of AL amyloidosis, confirmed by histology and typed with immunohistochemistry, immunoelectron microscopy or mass spectrometry.\n2. Newly diagnosed or previous treated AL amyloidosis\n3. Patients must be ≥ 18 years of age.\n4. ECOG performance status 0, 1 or 2.\n5. Measurable disease defined by at least one of the following:\n\n   ① serum free light chain (FLC) ≥2.0 mg\u002FdL (20 mg\u002FL) with an abnormal kappa:lambda ratio or the difference between involved and uninvolved free light chains (dFLC) ≥2mg\u002FdL (20 mg\u002FL).\n\n   ②. presence of a monoclonal spike that is ≥5 g\u002Fl.\n6. Symptomatic organ involvement (heart, kidney, liver\u002FGI tract, peripheral nervous system).\n7. Absolute neutrophil count (ANC) ≥1.0 X 10\\^9\u002FL, Hemoglobin ≥70 g\u002FL, Platelets ≥50 X 10\\^9\u002FL\n8. eGFR ≥20 mL\u002Fmin\u002F 1.73 m\\^2\n9. Written informed consent in accordance with local and institutional guidelines.\n10. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion Criteria:\n\n1. Fulfill with the criteria of active multiple myeloma or active lymphoplasmacytic lymphoma.\n2. Presence of other tumors which is\u002Fare in advanced malignant stage and has\u002Fhave systemic metastasis;\n3. Severe or persistent infection that cannot be effectively controlled;\n4. Presence of severe autoimmune diseases or immunodeficiency disease;\n5. Patients with active hepatitis B or hepatitis C (\\[HBVDNA+\\] or \\[HCVRNA+\\]);\n6. Patients with HIV infection or syphilis infection;\n7. Any situations that the researchers believe will increase the risks for the subject or affect the results of the study.","ALL","18 Years","90 Years",{"count":78,"type":79},40,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed or previous treated systemic light chain (AL) amyloidosis. Approximately 40 subjects will receive therapy with bortezomib, pomalidomide, and dexamethasone. The primary outcome is hematologic very good partial response and complete response rate at 6 months.",[85],"Systemic Amyloidosis","2024-12-25",{"date":88,"type":89},"2024-12-30","ACTUAL",{"date":91,"type":89},"2024-05-06",{"date":93,"type":79},"2026-12",{"name":65,"class":6},1]